Literature DB >> 28032631

Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network.

C Mancusi1,2, M A Losi1,2, R Izzo1,3, G Canciello1,2, M V Manzi1,3, A Sforza1,3, N De Luca1,3, B Trimarco1,2, G de Simone1,3.   

Abstract

Reduced myocardial mechano-energetic efficiency (MEE), estimated as stroke volume/heart rate ratio per g of left ventricular (LV) mass (LVM), and expressed in μl s-1 g-1 (MEEi), is a strong predictor of cardiovascular (CV) events, independently of LV hypertrophy and other confounders, including type II diabetes (DM). Decreased MEEi is more frequent in patients with diabetes. In the present analysis we evaluated the interrelation among MEEi, DM and metabolic syndrome (MetS) in the setting of arterial hypertension. Hypertensive patients from the Campania Salute Network, free of prevalent CV disease and with ejection fraction >50% (n=12 503), were analysed. Coexistence of MetS and DM was ordinally categorized into 4 groups: 8235 patients with neither MetS nor DM (MetS-/DM-); 502 without MetS and with DM (MetS-/DM+); 3045 with MetS and without DM (MetS+/DM-); and 721 with MetS and DM (MetS+/DM+). After controlling for sex, systolic blood pressure, body mass index, relative wall thickness (RWT), antihypertensive medications and type of antidiabetic therapy, MEEi was 333 μl s-1 g-1 in MetS-/DM-, 328 in MetS-/DM+, 326 in MetS+/DM- and 319 in MetS+/DM+ (P for trend <0.0001). In pairwise comparisons (Sidak-adjusted), all conditions, except MetS-/DM+, were significantly different from MetS-/DM- (all P<0.02). No statistical difference was detected between MetS-/DM+ and MetS+/DM-. Both MetS and DM are associated with decreased MEEi in hypertensive patients, independently to each other, but the reduction is statistically less evident for MetS-/DM+. MetS+/DM+ patients have the lowest levels of MEEi, consistent with the alterations of energy supply associated with the combination of insulin resistance with insulin deficiency.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28032631     DOI: 10.1038/jhh.2016.88

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

1.  Low mechano-energetic efficiency is associated with future left ventricular systolic dysfunction in hypertensives.

Authors:  Maria V Manzi; Costantino Mancusi; Maria Lembo; Giovanni Esposito; Maria A E Rao; Giovanni de Simone; Carmine Morisco; Valentina Trimarco; Raffaele Izzo; Bruno Trimarco
Journal:  ESC Heart Fail       Date:  2022-04-28

2.  Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort.

Authors:  Costantino Mancusi; Giovanni de Simone; Lyle G Best; Wenyu Wang; Ying Zhang; Mary J Roman; Elisa T Lee; Barbara V Howard; Richard B Devereux
Journal:  Cardiovasc Diabetol       Date:  2019-04-30       Impact factor: 9.951

3.  CHA2DS2-VASc score and left atrial volume dilatation synergistically predict incident atrial fibrillation in hypertension: an observational study from the Campania Salute Network registry.

Authors:  Antonio Rapacciuolo; Costantino Mancusi; Grazia Canciello; Raffaele Izzo; Teresa Strisciuglio; Nicola de Luca; Giuseppe Ammirati; Giovanni de Simone; Bruno Trimarco; Maria-Angela Losi
Journal:  Sci Rep       Date:  2019-05-27       Impact factor: 4.379

4.  Determinants of improvement of left ventricular mechano-energetic efficiency in hypertensive patients.

Authors:  Maria Lembo; Valentina Trimarco; Maria Virginia Manzi; Costantino Mancusi; Giovanni Esposito; Salvatore Esposito; Carmine Morisco; Raffaele Izzo; Bruno Trimarco
Journal:  Front Cardiovasc Med       Date:  2022-07-28

5.  Carotid Atherosclerosis Predicts Blood Pressure Control in Patients With Hypertension: The Campania Salute Network Registry.

Authors:  Costantino Mancusi; Maria Virginia Manzi; Giovanni de Simone; Carmine Morisco; Maria Lembo; Emanuele Pilato; Raffaele Izzo; Valentina Trimarco; Nicola De Luca; Bruno Trimarco
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.